Randomised Trial of Proton vs. Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base -Clinical Phase III ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2010-2023

ABSTRACT

This study is a prospective randomised clinical phase III trial. The primary objective of this study is to evaluate, if the innovative therapy (carbon ion irradiation) in chordomas is superior to the standard proton treatment with respect to the local-progression free survival (LPFS). Detailed Description The study is a prospective randomised clinical phase III trial. The trial will be carried out at Heidelberger Ionenstrahl-Therapie (HIT) centre as monocentric trial.Proton therapy is the gold standard in the treatment of skull base chordomas. However, high-LET beams such as carbon ions theoretically offer biologic advantages by enhanced biologic effectiveness in slow-growing tumors. Up until now it was impossible to compare two different particle therapies, i.e. proton and carbon ion therapy directly with each other. The aim of this study is to find out, whether the biological advantages of carbon ion therapy mentioned above can also be clinically confirmed.Patients with skull base chordoma will be randomised to either proton or carbon ion radiation therapy. As a standard, patients will undergo non-invasive, rigid immobilization and target volume delineation will be carried out based on CT and MRI data. The biologically isoeffective target dose to the PTV in carbon ion treatment (accelerated dose) will be 63 Gy E ± 5% and 72 Gy E ± 5% (standard dose) in proton therapy respectively. Local-progression free survival (LPFS) will be analysed as primary end point. Toxicity and survival are the secondary end points. Also matters of interest are patterns of recurrence, prognostic factors and plan quality. More... »

URL

https://clinicaltrials.gov/show/NCT01182779

Related SciGraph Publications

  • 1999-06. Proton therapy for tumors of the skull base in STRAHLENTHERAPIE UND ONKOLOGIE
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "description": "This study is a prospective randomised clinical phase III trial. The primary objective of this study is to evaluate, if the innovative therapy (carbon ion irradiation) in chordomas is superior to the standard proton treatment with respect to the local-progression free survival (LPFS).\n\nDetailed Description\nThe study is a prospective randomised clinical phase III trial. The trial will be carried out at Heidelberger Ionenstrahl-Therapie (HIT) centre as monocentric trial.Proton therapy is the gold standard in the treatment of skull base chordomas. However, high-LET beams such as carbon ions theoretically offer biologic advantages by enhanced biologic effectiveness in slow-growing tumors. Up until now it was impossible to compare two different particle therapies, i.e. proton and carbon ion therapy directly with each other. The aim of this study is to find out, whether the biological advantages of carbon ion therapy mentioned above can also be clinically confirmed.Patients with skull base chordoma will be randomised to either proton or carbon ion radiation therapy. As a standard, patients will undergo non-invasive, rigid immobilization and target volume delineation will be carried out based on CT and MRI data. The biologically isoeffective target dose to the PTV in carbon ion treatment (accelerated dose) will be 63 Gy E \u00b1 5% and 72 Gy E \u00b1 5% (standard dose) in proton therapy respectively. Local-progression free survival (LPFS) will be analysed as primary end point. Toxicity and survival are the secondary end points. Also matters of interest are patterns of recurrence, prognostic factors and plan quality.", 
        "endDate": "2023-08", 
        "id": "sg:clinicaltrial.NCT01182779", 
        "keywords": [
          "local progression-free survival", 
          "clinical phase III trials", 
          "phase III trials", 
          "carbon ion radiation therapy", 
          "skull base chordomas", 
          "free survival", 
          "III trials", 
          "ion radiation therapy", 
          "radiation therapy", 
          "Gy E", 
          "end point", 
          "trial of protons", 
          "Secondary end points", 
          "primary end point", 
          "phase III study", 
          "patterns of recurrence", 
          "target volume delineation", 
          "carbon ion therapy", 
          "proton therapy", 
          "monocentric trial", 
          "III study", 
          "prognostic factors", 
          "target dose", 
          "innovative therapies", 
          "therapy", 
          "volume delineation", 
          "chordoma", 
          "patients", 
          "carbon ion treatment", 
          "trials", 
          "rigid immobilization", 
          "gold standard", 
          "biologic advantages", 
          "ion therapy", 
          "plan quality", 
          "survival", 
          "biologic effectiveness", 
          "proton treatment", 
          "treatment", 
          "MRI data", 
          "primary objective", 
          "particle therapy", 
          "biological advantages", 
          "recurrence", 
          "tumors", 
          "study", 
          "dose", 
          "CT", 
          "PTV", 
          "toxicity", 
          "aim", 
          "factors", 
          "matter of interest", 
          "center", 
          "standards", 
          "delineation", 
          "ion treatment", 
          "high-LET beams", 
          "objective", 
          "patterns", 
          "data", 
          "quality", 
          "effectiveness", 
          "point", 
          "carbon ions", 
          "detailed description", 
          "advantages", 
          "immobilization", 
          "interest", 
          "respect", 
          "matter", 
          "protons", 
          "description", 
          "beam", 
          "ions"
        ], 
        "name": "Randomised Trial of Proton vs. Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base -Clinical Phase III Study-", 
        "sameAs": [
          "https://app.dimensions.ai/details/clinical_trial/NCT01182779"
        ], 
        "sdDataset": "clinical_trials", 
        "sdDatePublished": "2022-10-01T07:01", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/clinical_trial/clinical_trial_1.jsonl", 
        "startDate": "2010-07", 
        "subjectOf": [
          {
            "id": "sg:pub.10.1007/bf03038890", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032828853", 
              "https://doi.org/10.1007/bf03038890"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "type": "MedicalStudy", 
        "url": "https://clinicaltrials.gov/show/NCT01182779"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01182779'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01182779'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01182779'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01182779'


     

    This table displays all metadata directly associated to this object as RDF triples.

    102 TRIPLES      15 PREDICATES      92 URIs      84 LITERALS      1 BLANK NODES

    Subject Predicate Object
    1 sg:clinicaltrial.NCT01182779 schema:about anzsrc-for:11
    2 anzsrc-for:1103
    3 anzsrc-for:1112
    4 schema:description This study is a prospective randomised clinical phase III trial. The primary objective of this study is to evaluate, if the innovative therapy (carbon ion irradiation) in chordomas is superior to the standard proton treatment with respect to the local-progression free survival (LPFS). Detailed Description The study is a prospective randomised clinical phase III trial. The trial will be carried out at Heidelberger Ionenstrahl-Therapie (HIT) centre as monocentric trial.Proton therapy is the gold standard in the treatment of skull base chordomas. However, high-LET beams such as carbon ions theoretically offer biologic advantages by enhanced biologic effectiveness in slow-growing tumors. Up until now it was impossible to compare two different particle therapies, i.e. proton and carbon ion therapy directly with each other. The aim of this study is to find out, whether the biological advantages of carbon ion therapy mentioned above can also be clinically confirmed.Patients with skull base chordoma will be randomised to either proton or carbon ion radiation therapy. As a standard, patients will undergo non-invasive, rigid immobilization and target volume delineation will be carried out based on CT and MRI data. The biologically isoeffective target dose to the PTV in carbon ion treatment (accelerated dose) will be 63 Gy E ± 5% and 72 Gy E ± 5% (standard dose) in proton therapy respectively. Local-progression free survival (LPFS) will be analysed as primary end point. Toxicity and survival are the secondary end points. Also matters of interest are patterns of recurrence, prognostic factors and plan quality.
    5 schema:endDate 2023-08
    6 schema:keywords CT
    7 Gy E
    8 III study
    9 III trials
    10 MRI data
    11 PTV
    12 Secondary end points
    13 advantages
    14 aim
    15 beam
    16 biologic advantages
    17 biologic effectiveness
    18 biological advantages
    19 carbon ion radiation therapy
    20 carbon ion therapy
    21 carbon ion treatment
    22 carbon ions
    23 center
    24 chordoma
    25 clinical phase III trials
    26 data
    27 delineation
    28 description
    29 detailed description
    30 dose
    31 effectiveness
    32 end point
    33 factors
    34 free survival
    35 gold standard
    36 high-LET beams
    37 immobilization
    38 innovative therapies
    39 interest
    40 ion radiation therapy
    41 ion therapy
    42 ion treatment
    43 ions
    44 local progression-free survival
    45 matter
    46 matter of interest
    47 monocentric trial
    48 objective
    49 particle therapy
    50 patients
    51 patterns
    52 patterns of recurrence
    53 phase III study
    54 phase III trials
    55 plan quality
    56 point
    57 primary end point
    58 primary objective
    59 prognostic factors
    60 proton therapy
    61 proton treatment
    62 protons
    63 quality
    64 radiation therapy
    65 recurrence
    66 respect
    67 rigid immobilization
    68 skull base chordomas
    69 standards
    70 study
    71 survival
    72 target dose
    73 target volume delineation
    74 therapy
    75 toxicity
    76 treatment
    77 trial of protons
    78 trials
    79 tumors
    80 volume delineation
    81 schema:name Randomised Trial of Proton vs. Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base -Clinical Phase III Study-
    82 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01182779
    83 schema:sdDatePublished 2022-10-01T07:01
    84 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    85 schema:sdPublisher N1aa5b153917841b5b8835cdf873770d0
    86 schema:startDate 2010-07
    87 schema:subjectOf sg:pub.10.1007/bf03038890
    88 schema:url https://clinicaltrials.gov/show/NCT01182779
    89 sgo:license sg:explorer/license/
    90 sgo:sdDataset clinical_trials
    91 rdf:type schema:MedicalStudy
    92 N1aa5b153917841b5b8835cdf873770d0 schema:name Springer Nature - SN SciGraph project
    93 rdf:type schema:Organization
    94 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    95 rdf:type schema:DefinedTerm
    96 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    97 rdf:type schema:DefinedTerm
    98 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    99 rdf:type schema:DefinedTerm
    100 sg:pub.10.1007/bf03038890 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032828853
    101 https://doi.org/10.1007/bf03038890
    102 rdf:type schema:CreativeWork
     




    Preview window. Press ESC to close (or click here)


    ...